Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data
Author:
Affiliation:
1. RTI Health Solutions, Research Triangle Park North Carolina USA
2. Eli Lilly and Company Indianapolis Indiana USA
Funder
This study was performed under a research contract between RTI Health Solutions and Eli Lilly and Company and was funded by Eli Lilly and Company.
Publisher
Wiley
Subject
Pharmacology (medical),Epidemiology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5103
Reference18 articles.
1. The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine
2. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
3. Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety
4. Safety of parathyroid hormone for the treatment of osteoporosis
5. Eli Lilly and Company.Forteo [package insert]. Revised 2012.http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021318s012lbl.pdf(Accessed May 16 2016).
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The Risk of Developing Osteosarcoma After Teriparatide Use: A Systematic Review;Orthopedic Research and Reviews;2023-09
2. Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO);Osteoporosis International;2023-06-23
3. Treatment of Osteoporosis With Anabolic Agents and the Risk of Primary Bone Cancers: A Study of 44,728 Patients Treated With Teriparatide and Abaloparatide;Journal of the American Academy of Orthopaedic Surgeons;2023-03-10
4. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline;European Journal of Endocrinology;2022-10-25
5. Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates;JBMR Plus;2022-08-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3